News | October 15, 2008

Philips, Celsion Target Drug Delivery with MR-guided HIFU

October 16, 2008 - Royal Philips Electronics and Celsion Corp. have signed a joint research agreement focusing on a new cancer treatment that combines Philips’ ultrasound technology with Celsion’s drug delivery solution to target tumors with high concentrations of a cancer-fighting drug.

Under the terms of the agreement, Philips and Celsion will collaborate to explore the potential for using Philips’ investigational magnetic resonance imaging (MRI)-guided high intensity focused ultrasound (HIFU) system in combination with Celsion’s leading drug candidate, ThermoDox, to treat a broad range of cancers. The research uses the HIFU system to position doxorubicin, an approved and frequently used anti-cancer drug, and to create a mild hyperthermia that releases the drug directly into the tumor. The result would be the ability to treat tumors that would otherwise be inaccessible.

The Philips HIFU system is designed to precisely control and deliver energy noninvasively to targeted tissues. HIFU is being researched to evaluate its use in activating Celsion’s temperature-sensitive liposome technology to release encapsulated chemotherapy drugs such as doxorubicin. Doxorubicin is the potent anticancer agent in ThermoDox. By using Philips’ HIFU technology to deliver targeted, localized activation temperatures, Philips’ and Celsion’s research will explore the potential for ThermoDox to noninvasively treat a number of solid tumor cancers that may be susceptible to the combination of a high concentration of doxorubicin and concurrent hyperthermia.

"Localized drug delivery is being evaluated to determine the potential for increasing the potency of drugs in their target regions with equal or less toxicity to critical organs,” said Falko Busse, vice president and chief technology officer, MR, for Philips Healthcare. “The Philips MR-HIFU system could be a powerful tool to deliver these thermally activated drugs. Our volumetric heating with feedback technology is being designed to allow control of both the tissue temperature and the heating area. We are very excited about this research collaboration with Celsion in the promising field of localized drug delivery."

Philips’ commitment develop cancer treatments is complements Celsion’s mission is to bring temperature-sensitive liposomal technology to treat difficult cancers. Philips’ MRI-guided HIFU technology has the potential to heat a defined area while providing a real-time visualization of the heated area through the use of MRI.”

Philips and Celsion are conducting research to test two premises. First, ThermoDox has the potential to eliminate cancer cells that may otherwise remain viable and be responsible for secondary tumors by using HIFU to aid in releasing the concentrated drug within and around the margins of the heated area. Second, using HIFU in the low temperature activation mode in combination with ThermoDox has the potential to provide a means to deliver high concentrations of chemotherapeutics to multiple sites at virtually any location in the body.

For more information: www.medical.philips.com and www.celsion.com

Related Content

Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Imaging | January 17, 2018
January 17, 2018 — Philips recently announced the launch of Technology Maximizer, a cross-modality program designed t
New Vascular Ultrasound Registry Looks to Enhance Patient Care
News | Cardiovascular Ultrasound | January 17, 2018
The Society for Vascular Ultrasound (SVU), the Society for Vascular Surgery (SVS) and Medstreaming-M2S announced the...
Sponsored Content | Videos | Ultrasound Imaging | January 11, 2018
Mindray recently featured a new upgrade for its premium Resona 7 ultrasound system at the Radiological Society of North...
New International Report Provides Comprehensive Guide to Imaging in Chagas Heart Disease
News | Cardiovascular Ultrasound | January 03, 2018
Chagas disease (ChD), an infectious parasitic disease transmitted primarily by triatomine insects, has become a...
Bay Labs Completes $5.5 Million Series A Financing for AI-Driven Ultrasound
News | Cardiovascular Ultrasound | December 21, 2017
December 21, 2017 — Bay Labs, a medical technology company applying...
Toshiba Medical Introduces New Entry-Level Aplio i600 Ultrasound Platform
News | Ultrasound Imaging | December 21, 2017
Toshiba Medical, a Canon Group company, showcased the Aplio i600, the newest addition to the premium Aplio i-series...
Videos | RSNA 2017 | December 20, 2017
ITN and DAIC Editor Dave Fornell takes a tour of some of the most interesting new medical imaging technologies on the
GE and NVIDIA Unveil Artificial Intelligence Upgrades to CT, Ultrasound and Analytics Solutions
Technology | Artificial Intelligence | December 14, 2017
At the 2017 Radiological Society of North America (RSNA) Annual Meeting, GE Healthcare and NVIDIA announced a series of...
Hitachi Highlights Arietta 850 Premium Ultrasound System at RSNA 2017
News | Ultrasound Imaging | December 05, 2017
Hitachi Healthcare exhibited their latest premium ultrasound system, the Arietta 850, at the 2017 Radiological Society...
Toshiba Medical Rolls Out Interactive Learning Tools for Ultrasound and Vascular Training
News | Ultrasound Imaging | December 04, 2017
Toshiba Medical, a Canon Group company, introduced new educational tools and interactive learning resources to help...
Overlay Init